KENLIFABI Trademark

Trademark Overview

On Wednesday, July 14, 2021, a trademark application was filed for KENLIFABI with the United States Patent and Trademark Office. The USPTO has given the KENLIFABI trademark a serial number of 90827353. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, July 18, 2024. This trademark is owned by Idorsia Pharmaceuticals Ltd. The KENLIFABI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders
kenlifabi

General Information

Serial Number90827353
Word MarkKENLIFABI
Filing DateWednesday, July 14, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, July 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 15, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIdorsia Pharmaceuticals Ltd
Party Type20 - Owner at Publication
Legal Entity Type09 - Joint Stock Company
AddressAllschwil 4123
CH
Party NameIdorsia Pharmaceuticals Ltd
Party Type10 - Original Applicant
Legal Entity Type09 - Joint Stock Company
AddressAllschwil 4123
CH

Trademark Events

Event DateEvent Description
Monday, April 4, 2022ASSIGNED TO EXAMINER
Saturday, July 17, 2021NEW APPLICATION ENTERED
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 11, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 11, 2022NON-FINAL ACTION WRITTEN
Monday, April 11, 2022NON-FINAL ACTION E-MAILED
Wednesday, June 15, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, June 15, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, June 15, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 28, 2023SOU EXTENSION 2 FILED
Friday, July 28, 2023SOU EXTENSION 2 GRANTED
Tuesday, August 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 27, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023SOU EXTENSION 1 FILED
Wednesday, February 22, 2023SOU EXTENSION 1 GRANTED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 28, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 27, 2024SOU EXTENSION 3 GRANTED
Tuesday, February 27, 2024SOU EXTENSION 3 FILED
Thursday, July 18, 2024SOU EXTENSION 4 FILED
Thursday, July 18, 2024SOU EXTENSION 4 GRANTED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 18, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

kenlifabi fabry treatment disease glycolipid storage disorders sequelae symptoms preparations pharmaceutical